These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 15841896)

  • 21. Direct measurement of health care costs.
    Smith MW; Barnett PG
    Med Care Res Rev; 2003 Sep; 60(3 Suppl):74S-91S. PubMed ID: 15095547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in measuring patient outcomes.
    Strickland OL
    Nurs Clin North Am; 1997 Sep; 32(3):495-512. PubMed ID: 9254635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics: state of the art in 1997.
    Schulman KA; Linas BP
    Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data collection methods in prospective economic evaluations: how accurate are the results?
    Evans CJ; Crawford B
    Value Health; 2000; 3(4):277-86. PubMed ID: 16464192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
    van Dongen JM; El Alili M; Varga AN; Guevara Morel AE; Jornada Ben A; Khorrami M; van Tulder MW; Bosmans JE
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):27-37. PubMed ID: 31731882
    [No Abstract]   [Full Text] [Related]  

  • 26. Issues for statisticians in pharmaco-economic evaluations.
    Grieve AP
    Stat Med; 1998 Aug 15-30; 17(15-16):1715-23; discussion 1741-3. PubMed ID: 9749442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance.
    Oliver A; Pritchard C
    Value Health; 2000; 3 Suppl 1():7-14. PubMed ID: 16464205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACCP: economic evaluations of clinical pharmacy services: 2001-2005.
    Perez A; Doloresco F; Hoffman JM; Meek PD; Touchette DR; Vermeulen LC; Schumock GT;
    Pharmacotherapy; 2009 Jan; 29(1):128. PubMed ID: 19113803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial.
    Schulman KA; Glick H; Buxton M; Sculpher M; Backhouse M; Bell L; Eisenberg JM
    Control Clin Trials; 1996 Aug; 17(4):304-15. PubMed ID: 8889345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring the value of public health systems: the disconnect between health economists and public health practitioners.
    Neumann PJ; Jacobson PD; Palmer JA
    Am J Public Health; 2008 Dec; 98(12):2173-80. PubMed ID: 18923123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the validity of economic evaluations alongside controlled trials.
    Dixon S; Deverill M; Gannon M; Brazier J; Haggard M
    J Health Serv Res Policy; 1999 Jul; 4(3):161-3. PubMed ID: 10538881
    [No Abstract]   [Full Text] [Related]  

  • 32. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial.
    Sullivan SD; Liljas B; Buxton M; Lamm CJ; O'Byrne P; Tan WC; Weiss KB;
    Control Clin Trials; 2001 Aug; 22(4):420-37. PubMed ID: 11514042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trials in medical rehabilitation research.
    Tate DG; Findley T; Dijkers M; Nobunaga AI; Karunas RB
    Am J Phys Med Rehabil; 1999; 78(5):486-99. PubMed ID: 10493460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current state and challenges of pharmacoeconomic evaluation in Korea].
    Choi SE
    J Prev Med Public Health; 2008 Mar; 41(2):74-9. PubMed ID: 18385546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economic evaluations help inform payers of the best use of scarce health care resources.
    O'Reilly D; Gaebel K; Xie F; Tarride JE; Goeree R
    Int J Circumpolar Health; 2011 Sep; 70(4):417-27. PubMed ID: 21924008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of confidence intervals and sample size calculations in health economic studies.
    Sacristán JA; Day SJ; Navarro O; Ramos J; Hernández JM
    Ann Pharmacother; 1995; 29(7-8):719-25. PubMed ID: 8520090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable.
    Garrison LP
    Value Health; 2003; 6(1):6-8. PubMed ID: 12535233
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
    Revicki DA; Frank L
    Pharmacoeconomics; 1999 May; 15(5):423-34. PubMed ID: 10537960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis and interpretation of cost data in randomised controlled trials: review of published studies.
    Barber JA; Thompson SG
    BMJ; 1998 Oct; 317(7167):1195-200. PubMed ID: 9794854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.